NEW YORK – Inivata has launched a patient-specific circulating-tumor DNA (ctDNA) assay for minimal residual disease (MRD) detection and cancer relapse monitoring, and anticipates offering the assay to biopharmaceutical companies for clinical cancer research.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.